2026 ICD-10-CM Diagnosis Code N62Hypertrophy of breast
ICD-10-CM Codes›N00–N99›N60-N65›N62
- Billable — Valid for Submission
- Chronic Condition
N62 is a billable ICD-10-CM diagnosis code for hypertrophy of breast. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 600 through 601. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Nonmalignant breast conditions.
Code Identity
Code Classification
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Abnormally short little finger
- Atypical ductal hyperplasia of breast
- Atypical hyperplasia of breast
- Atypical lobular hyperplasia of breast
- Breast lobule hyperplasia
- Familial juvenile hypertrophy of breast
- Finding related to development of the breasts
- Gigantomastia
- Gynecomastia
- Gynecomastia caused by drug
- Gynecomastia caused by human chorionic gonadotrophin
- Hyperplasia of mammary duct
- Hypertrophy of breast
- Hypertrophy of gland of Montgomery
- Hypoplasia of distal phalanx of foot
- Idiopathic gynecomastia
- Infantile breast hypertrophy
- Large breast
- Mammary digital nail syndrome
- Massive pubertal hypertrophy of breast
- Overdeveloped breasts
- Pseudoangiomatous stromal hyperplasia of breast
- Pubertal breast hypertrophy
- Pubertal gynecomastia
- Size of breast - finding
- Thelarche
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- Gynecomastia
- Hypertrophy of breast NOS
- Massive pubertal hypertrophy of breast
Type 1 Excludes
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
A type 1 excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
- Gynecomastia - N62
- epithelial - L85.9
- nipple - N62
- breast - N62
- pubertal, massive - N62
- senile (parenchymatous) - N62
- nipple - N62
- Mammoplasia - N62
- Mastoplasia, mastoplastia - N62
External Cause of Injuries IndexGuidance
References for this code in the External Cause of Injuries Index.
- Excess, excessive, excessively
- development, breast
- Gynecomastia
- Hyperplasia, hyperplastic
- epithelial
- nipple
- Hypertrophy, hypertrophic
- breast
- Hypertrophy, hypertrophic
- breast
- pubertal, massive
- Hypertrophy, hypertrophic
- breast
- senile (parenchymatous)
- Hypertrophy, hypertrophic
- nipple
- Mammoplasia
- Mastoplasia, mastoplastia
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Gynecomastia
enlargement of the breast in the males, caused by an excess of estrogens. physiological gynecomastia is normally observed in newborns; adolescent; and aging males.Gynecomastia, CTCAE|Gynecomastia|Gynecomastia|Gynecomastia (Priority 2)|Gynecomastia, CTCAE 5.0
a disorder characterized by excessive development of the breasts in males.17-Beta-Hydroxysteroid Dehydrogenase 3 Deficiency|17 Beta HSD3 Deficiency|17 beta HSD3 Deficiency|Pseudohermaphroditism, Male, with Gynecomastia
decreased activity of the steroidogenic enzyme, 17-beta-hydroxysteroid dehydrogenase, associated with mutation(s) in the hsd17b3 gene, leading to reduced testosterone production.Grade 1 Gynecomastia, CTCAE|Grade 1 Gynecomastia
asymptomaticGrade 2 Gynecomastia, CTCAE|Grade 2 Gynecomastia|Grade 2 Gynecomastia
symptomatic (e.g., pain or psychosocial impact)Grade 3 Gynecomastia, CTCAE|Grade 3 Gynecomastia|Grade 3 Gynecomastia
severe symptoms; elective operative intervention indicatedGynecomastia
a non-neoplastic focal or diffuse proliferation of glandular tissue of breast in males.Gynecomastia, CTCAE 5.0|Gynecomastia|Gynecomastia|Gynecomastia (Priority 2)
a disorder characterized by excessive development of the breasts in males.Pathological Gynecomastia
gynecomastia that is due to exogenous substances or disease processes.Pubertal Gynecomastia|Transient Gynecomastia|Transient Gynecomastia
gynecomastia that occurs during puberty and is not due to exogenous substances or disease processes.
Patient EducationClinical
Breast Diseases
Breast diseases include various conditions and changes in your breast. Most women experience breast changes at some time. Your age, hormone levels, and medicines you take may cause lumps, bumps, and discharges of fluids that are not breast milk.
The full article covers:
- What are breast diseases?
- What are the symptoms of breast disease?
- How are breast diseases diagnosed?
- What are the treatments for breast disease?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert N62 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About N62Overview
Is N62 (Hypertrophy of breast) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report hypertrophy of breast on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does N62 group to?
When hypertrophy of breast is the principal diagnosis on an inpatient stay, it groups to MS-DRG 600, 601, with relative weights from 0.6050 to 1.0416 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of N62?
Under the General Equivalence Mappings, hypertrophy of breast converts to ICD-9-CM 611.1 (hypertrophy of breast). The mapping is a direct match.
Footnotes
[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:
- The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
- The condition places limitations on self-care, independent living, and social interactions.
